STAT+: Hims’ sales miss as telehealth competition grows
Why this matters: health reporting relevant to everyday decisions and well-being.
Want to stay on top of the science and politics driving biotech today?&#x A0;Sign up&#x A0;to get our biotech newsletter in your inbox. Good morning. My colleagues today launched a series investigating one of the biggest public health crises in the U.S. — the alcohol epidemic. Their stories will examine factors ranging from the influence of the alcohol industry to the gaps in treatment options for addiction. Read part 1 of the series here. The need-to-know this morning Rigel Pharma will market the newly approved breast cancer drug Veppanu under a commercialization agreement signed with Arvinas and Pfizer.  Roche received European clearance for a new blood test to detect early Alzheimer’s disease.  BridgeBio submitted an application to the FDA seeking approval of its drug encaleret to treat patients with autosomal dominant hypocalcemia type 1, or ADh2, a rare genetic disease that causes low calcium levels in the blood. Bristol turns to Chinese drugmaker for early-stage pipeline restock Bristol Myers Squibb this morning announced a partnership with Hengrui Pharma covering more than a dozen early-stage programs, the latest and a notably large case of a global pharmaceutical company looking to China for its next medicines, my colleague Andrew Joseph reports.Continue to STAT+ to read the full story…